Latest Neurology News

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.

Compumedics reported a record $60.3 million in FY26 revenue, driven by an 18% year-on-year increase and a 70% jump in SaaS recurring revenues from Somfit and Nexus 360. The company resolved supply chain disruptions and targets faster EBITDA growth in FY27.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

dorsaVi has secured exclusive rights to two key robotics patents from NTU Singapore, filling critical gaps in safety control and data acquisition to expand into collaborative robotics and exoskeleton markets.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Actinogen Medical has obtained positive scientific advice from the European Medicines Agency that aligns with prior FDA guidance, clarifying regulatory requirements for its Alzheimer’s drug Xanamem and paving the way for a streamlined approval process in major markets.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.